Mindmed successfully completes phase 1 clinical trial of 18-mc

- last subject completed study in late 2021 with topline results expected in early 2022 - - results to inform design of phase 2a study in individuals undergoing supervised opioid withdrawal - new york, jan. 4, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a leading biotech company developing psychedelic-derived therapies, today announced the completion of its phase 1 clinical trial of 18-mc, the company's non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder. the trial was completed in december 2021 with topline results expected in early 2022.
MNMD Ratings Summary
MNMD Quant Ranking